Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Gynecol Endocrinol ; 39(1): 2264405, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37811796

RESUMO

OBJECTIVES: The objective is to assess the perception of gynecologists regarding patients' adherence to vulvovaginal atrophy (VVA) treatments, to evaluate the gynecologists' opinions on what their patients think about treatment adherence, and to compare the gynecologists' opinions with the patients' own perceptions within the CRETA study. METHODS: Spanish gynecologists who participated in the CRETA study were asked to fill out an online 41-item questionnaire to evaluate their views on VVA management. RESULTS: From 29 centers across Spain, 44 gynecologists completed the survey. Their mean age was 47.2 years old, two-thirds of them were women, and the average professional experience was over 20 years. According to the gynecologists, the therapy most frequently used by VVA-diagnosed women was vaginal moisturizers (45.5%), followed by local estrogen therapy (36.4%) and ospemifene (18.2%). Nevertheless, ospemifene was viewed as the therapeutic option with the most efficacy, easiest route of administration, shorter time to symptom improvement, lower percentage of dropouts, and higher treatment adherence. CONCLUSIONS: Spanish gynecologists are in general agreement with their patients regarding VVA treatment preferences and the main issues for adherence and effectiveness. However, there is an opportunity for doctor-patient communication improvement. Among the three therapeutic options evaluated, ospemifene is regarded as offering some competitive advantages.


Assuntos
Ginecologista , Tamoxifeno , Vagina , Doenças Vaginais , Vulva , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Atrofia/tratamento farmacológico , Atrofia/patologia , Atenção à Saúde , Percepção , Pós-Menopausa , Tamoxifeno/uso terapêutico , Vagina/patologia , Doenças Vaginais/tratamento farmacológico , Doenças Vaginais/patologia , Vulva/patologia , Cooperação e Adesão ao Tratamento
2.
Rev. chil. obstet. ginecol ; 78(6): 455-459, 2013. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-702353

RESUMO

La catarata congénita (CC) es una patología poco frecuente en nuestro medio frente a los países en desarrollo donde constituye la etiología más frecuente de ceguera infantil. La prevención de deterioro visual debido a esta patología es parte del programa de la OMS cuyo objetivo es la eliminación de ceguera evitable en el año 2020. Presentamos el caso de una gestante en la que el diagnóstico prenatal se realizó en la ecografía morfológica. Si somos capaces de realizar este diagnóstico podremos evitar el deterioro precoz de la función visual del recién nacido. Así, la identificación de ambos cristalinos debe de formar parte de las estructuras a reconocer de forma obligada en la ecografía morfológica.


Congenital cataract is a rare disease in our environment opposite developing countries where it is the most frequent etiology of childhood blindness. Prevention of visual impairment due to this pathology is a part of the WHO programme whose objective is the elimination of avoidable blindness by the year 2020. We present the case of a pregnant woman that prenatal diagnosis was made on mid- trimester ultrasound. If we are able to perform this diagnosis, we will be able to prevent early deterioration of visual function of the newborn. Thus, identification of both crystalline should be part of the structures to recognize in the mid- trimester ultrasound.


Assuntos
Humanos , Adulto , Feminino , Gravidez , Catarata/congênito , Catarata , Ultrassonografia Pré-Natal , Diagnóstico Diferencial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA